Presentation (CTI)

OBJECTIVES: Highlight the economic impact of AEs on the total cost of chemotherapy treatment, showing their significance and how they can exceed the cost of using new technologies. In addition to demonstrating how the rational of resource allocation can improve patients' lives
METHODS: A literature review was carried out to gather the most frequent AEs in platinum-based chemotherapy treatment. AEs with more than 30% prevalence were then listed. For these, a micro-funding of management and treatment was made based on the values ​​practiced in the Brazilian private health system
RESULTS: From the literature review, the most common AEs in patients with bladder cancer, being treated with platinum-based chemotherapy were anemia (57%), neutropenia (42%) and nausea (39%). For the treatment of each AE, the standard treatment indicated by national cancer treatment guidelines was considered. So, it was calculated that for one treatment of each patient who presented these AEs in a regimen of 6 cycles of platinum-based chemotherapy we would have the following costs: anemia R$325.45, neutropenia approximately R$247 thousand and nausea R$8.2 thousand.
CONCLUSIONS: Bladder cancer treatment with platinum-based chemotherapy can result in costs up to 800% higher than the price of the drugs themselves. To avoid unnecessary costs, lessen the impact of AEs on patients' lives, and improve resource utilization, implementing smart stratification and new treatment technologies can provide a valuable solution.